Huiqiang Huang
9 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Orelabrutinib in Combination With Thiotepa in Refractory and Relapsed Primary CNS Lymphoma (NCT05021770) | Huiqiang Huang | 2021-12-01 |
| Tislelizumab in Combination With Lenalidomide in Refractory and Relapsed Elderly Patients With Non-GCB DLBCL (NCT04796857) | Huiqiang Huang | 2021-03-31 |
| Ibrutinib With Methotrexate and Temozolomide for Patients With Newly Diagnosed Primary CNS Lymphoma (NCT04514393) | Huiqiang Huang | 2020-10-10 |
| Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL (NCT04476459) | Huiqiang Huang | 2020-07-23 |
| Toripalimab Plus Rituximab Followed by R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma (NCT04058470) | Huiqiang Huang | 2020-04-24 |
| Rituximab and Pegylated Interferon α-2b in Patients With Indolent B-cell Lymphoma (NCT04246359) | Huiqiang Huang | 2020-01-15 |
| Sintilimab in Combination With Chidamide in Refractory and Relapsed ENKTCL (NCT03820596) | Huiqiang Huang | 2019-03-29 |
Track Huiqiang Huang automatically
Every clearance here is in the API, with alerts when new ones post.